Vincent Romanet

JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

Maria Kleppe, Minsuk Kwak, Priya Koppikar et al. · Cancer Discovery · 2015 · 302 citations · Full text

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

Adrian Britschgi, Rita Andraos, Heike Brinkhaus et al. · Cancer Cell · 2012 · 240 citations · Full text

Metastatic Breast Cancer, Signaling Pathway, Breast Oncology +10

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Oliver Weigert, Andrew A. Lane, Liat Bird et al. · The Journal of Experimental Medicine · 2012 · 161 citations · Full text

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

Sara C. Meyer, Matthew D. Keller, Sophia Chiu et al. · Cancer Cell · 2015 · 151 citations

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

Shuo-Chieh Wu, Loretta S. Li, Nadja Kopp et al. · Cancer Cell · 2015 · 120 citations · Full text

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Malignant Blood Disorder +6